BioCentury
ARTICLE | Clinical News

FDA reviewing Agile's resubmitted NDA for contraceptive

August 28, 2017 11:07 PM UTC

Agile Therapeutics Inc. (NASDAQ:AGRX) said FDA accepted for review its resubmitted NDA for Twirla (seven-day contraceptive patch, AG200-15). Its PDUFA date is Dec. 26...